Out-of-pocket costs that Medicare Part D enrollees will pay next year for brand-name drugs will rise by an average of 40% for preferred drugs and 30% for nonpreferred drugs, according to an Avalere Health study. Copays for nonpreferred generic drugs will drop by about 43% and will stay about the same for preferred generics, the study found.

Related Summaries